enGene Therapeutics: Jason Duncan holds 0 direct shares

Available on EDGAR 11/13/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

enGene Therapeutics Inc. (ENGN) reported that its Chief Legal & Admin Officer Jason Duncan had no securities beneficially held directly, with 0 direct shares listed on November 9, 2026.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Duncan Jason

Role Chief Legal & Admin Officer

Type	Security	Shares	Price	Value
Holding	No securities beneficially held	--	--	--

Holdings: No securities beneficially held — 0 shares (Direct)

Key Figures

Direct shares beneficially held: 0 shares

1 metrics

Direct shares beneficially held 0 shares Jason Duncan, Chief Legal & Admin Officer; November 9, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ENGN shares did Jason Duncan report holding directly?

Jason Duncan's Form 3 lists 0 shares beneficially held directly on November 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Duncan Jason

(Last) (First) (Middle)

C/O 4868 RUE LEVY

SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
11/09/2026

3. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Admin Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities beneficially held	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Elizabeth Shortsleeve as attorney-in fact for Jason Duncan	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)